AstraZeneca entered an agreement to acquire Neogene Therapeutics Inc., a global clinical-stage biotechnology company focused on the discovery, development, and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) targeting cancer, for a total consideration of up to $320 million. This will include an initial payment of $200 million on closing, and a further $120 milion in potential milestones.   The transaction is expected to close 1Q23, subject to customary closing conditions an...